55
https://pubmed.ncbi.nlm.nih.gov/38117676
The abstract proposes a new “KYNA-NMDA-α7nAChR-centric” approach to treating substance use disorders by achieving kynurenic acid (KYNA) homeostasis through integrative pathophysiology and pharmacology, with a focus on the kynurenine pathway and investigational medications such as memantine, galantamine, and N-acetylcysteine.